The research team, led by scientists at the Reproductive Medical Center of the First Affiliated Hospital of Sun Yat-Sen University in Guangzhou, set out to determine what happens to early neural differentiation when BMAL1 is removed from the picture. Using CRISPR-Cas9 genome editing, they generated human embryonic stem cell lines lacking functional BMAL1 and then pushed those cells, alongside unedited controls, to differentiate into neural stem cells. The results were striking. Loss of BMAL1 did not compromise the cells’ pluripotency; the edited stem cells retained their characteristic ability to self-renew and to express the canonical markers of an undifferentiated state. What failed instead was the transition itself.

When the BMAL1-deficient cells were directed toward a neural fate, the process faltered at multiple levels. The cells formed defective neural rosettes, the distinctive rosette-shaped structures that emerging neural epithelial tissue normally organizes into during in vitro differentiation and that serve as a hallmark of successful neural induction. Gene expression analysis confirmed the visual impression: programs of neural lineage genes were broadly suppressed in the absence of BMAL1, while the pluripotency network remained stubbornly intact. In effect, the cells stayed parked in their stem cell identity, unable to execute the developmental script that would normally transform them into progenitors of the nervous system.

To understand how a circadian factor could exert such authority over this developmental decision, the researchers combined transcriptomic profiling with CUT&Tag, a technique that maps where a protein binds across the genome and which chemical marks accompany it. These experiments revealed that BMAL1 directly occupies and regulates genes involved in embryonic development and neurogenesis, placing it squarely upstream of the transcriptional events required for neural commitment. But transcriptional control alone could not account for everything the team observed, so they widened the lens to include a layer of regulation that operates after genes are transcribed: N6-methyladenosine, or m6A, the most abundant internal chemical modification found in eukaryotic messenger RNA.

m6A modification has emerged over the past decade as a master regulator of RNA fate. By methylating specific adenosine bases within transcripts, cells can influence how long a given RNA survives, how efficiently it is translated into protein, and how it is processed. The modification is installed by writer enzymes, removed by erasers, and interpreted by reader proteins, of which YTHDF2 is one of the best characterized, typically directing methylated transcripts toward degradation or altered translation. m6A is known to be a key regulator of early development, and the new study shows that its landscape is dramatically reshaped when BMAL1 is lost.

Integrated m6A profiling across the transcriptome demonstrated that the distribution of the modification was altered in BMAL1-deficient cells, with a particularly notable reduction in m6A enrichment near the transcription end sites of genes whose expression had declined. In other words, the downregulation of neural genes in these cells was accompanied by a specific erosion of m6A marks at the tail ends of their transcripts, hinting that BMAL1’s influence extends beyond simply switching genes on and off at the DNA level. The team then asked what might be responsible for this altered modification pattern and made a pivotal observation: although YTHDF2 RNA levels were not proportionally affected, the amount of YTHDF2 protein plummeted in cells lacking BMAL1.

The mechanism behind this protein loss turned out to be elegantly convoluted. Through a combination of binding assays and transcript analysis, the researchers showed that BMAL1 binds to an E-box motif, the classic DNA sequence recognized by circadian transcription factors, within the promoter of the YTHDF2 gene. Intriguingly, BMAL1 also regulates alternative splicing of YTHDF2 transcripts, biasing production toward a splice variant that carries a highly structured five-prime untranslated region, the segment of the RNA that precedes the protein-coding sequence. Highly structured untranslated regions impede the ribosome’s progress, and the team confirmed that this variant is translated with markedly reduced efficiency. The net consequence is that loss of BMAL1 drains the cellular pool of YTHDF2 protein through a combination of transcriptional and post-transcriptional effects on the same gene.

To establish that this mechanism is genuinely causal rather than merely correlative, the researchers performed two decisive experiments. First, they used genome editing to disrupt the E-box motif in the YTHDF2 promoter, severing BMAL1’s direct grip on the gene. These edited cells phenocopied BMAL1 deficiency, displaying impaired neural differentiation despite the presence of a normal BMAL1 gene, which confirmed that the promoter interaction is a required element of the pathway. Second, they carried out functional rescue experiments, forcing YTHDF2 overexpression in BMAL1-deficient cells. This intervention partially restored the neural differentiation defects, demonstrating that YTHDF2 sits downstream of BMAL1 in the causal chain and that replenishing it can compensate for a substantial share of the damage caused by losing the clock factor.

Taken together, the study delineates what the authors describe as a BMAL1-m6A-YTHDF2 regulatory axis, a pathway that integrates transcriptional control, RNA modification and translational regulation into a single governing circuit for early human neural differentiation. The conceptual significance of this integration is considerable. Circadian biology and epitranscriptomics, the study of RNA chemical modifications, have largely progressed as parallel fields, and this work provides one of the clearest demonstrations that a circadian factor can act as a command node connecting the two. It also reframes BMAL1 itself: a protein best known for driving rhythmic gene expression in mature tissues is revealed to be a developmental gatekeeper whose removal leaves stem cells developmentally stalled.

The findings also carry implications that extend well beyond the culture dish. Circadian disruption, whether from shift work, sleep irregularity or other modern lifestyle pressures, is increasingly associated with adverse pregnancy and neurodevelopmental outcomes, but the molecular routes linking clock perturbation to developmental failure have remained speculative. By identifying a concrete mechanism through which BMAL1 loss derails human neural specification, the study provides a testable framework for how circadian disturbance could contribute to neurodevelopmental disorders. For regenerative medicine, the work suggests that protocols for deriving neural cells from human pluripotent stem cells, which are foundational to disease modeling and future cell therapies, may need to account for circadian factor status and m6A reader levels as quality-control variables. And for basic biology, it raises the possibility that the circadian system’s influence on development is broader and deeper than the daily rhythms it is famous for, operating at the level of RNA chemistry to shape which cells become neurons in the first place.

Subject of Research: BMAL1 regulation of human embryonic stem cell neural differentiation via YTHDF2-dependent m6A modification

Article Title: BMAL1 regulates human embryonic stem cell neurodifferentiation through YTHDF2-dependent m6A modification

Article References: Cai, B., Wen, T., Wang, B., Zeng, Y., Hou, W., Liu, X., Jin, Z., Ge, X., Cun, Y., Zhou, C., & Xu, Y. (2026). BMAL1 regulates human embryonic stem cell neurodifferentiation through YTHDF2-dependent m6A modification. Genome Biology. https://doi.org/10.1186/s13059-026-04276-8

Image Credits: AI Generated

DOI: 10.1186/s13059-026-04276-8

Keywords: BMAL1, circadian rhythm, human embryonic stem cells, neural differentiation, m6A modification, YTHDF2, CRISPR-Cas9, neurodevelopment, RNA modification, neural stem cells, alternative splicing, Genome Biology

The study, led by Yinliang Zhang, Xiaochen Gai, Dong Zhao and Yongsheng Chang, with contributions from a team at Tianjin Medical University, Capital Medical University and Westlake University, began with a deceptively simple observation. When mice were exposed to cold, or when their fat cells were bathed in norepinephrine, the sympathetic neurotransmitter that surges during cold exposure, levels of ALKBH5 rose sharply in brown and subcutaneous fat. ALKBH5 belongs to a small family of enzymes that remove N6-methyladenosine, or m6A, the most abundant internal chemical modification on messenger RNA. By stripping these methyl marks, ALKBH5 can alter how long particular mRNA molecules survive before being degraded, and therefore how much protein the cell can manufacture from them.

Tracing the signal upstream, the investigators found that ALKBH5 expression is not a passive side effect of cold. Instead, norepinephrine binding to adrenergic receptors triggers the classic thermogenic signaling cascade: cyclic AMP accumulates, protein kinase A is activated, and the transcription factor CREB is phosphorylated and dispatched to the ALKBH5 gene, switching it on. Pharmacological tools confirmed the pathway’s logic. Forskolin and CW 008, which elevate cAMP signaling, boosted ALKBH5 expression in both mouse and human adipocytes, while the CREB inhibitor 666-15 and the PKA inhibitor H89 blunted that induction. In other words, the same sympathetic signal that commands fat cells to burn also instructs them to reprogram their RNA landscape.

The consequences of losing that reprogramming became clear when the team generated mice lacking ALKBH5 specifically in adipose tissue. Both male and female animals showed reduced thermogenic capacity, dropping their body temperature faster during acute cold exposure and dissipating less energy overall. When fed a high-fat diet, the knockout mice gained more weight, accumulated more fat mass and developed impaired glucose homeostasis compared with controls. Crucially, the metabolic defect appeared without changes in food intake or locomotor activity, pointing squarely at energy expenditure rather than appetite as the underlying problem. The findings applied across sexes, strengthening the physiological relevance of the pathway.

The mirror-image experiment proved equally striking. When the researchers delivered an ALKBH5 gene into brown and subcutaneous fat using adeno-associated virus, the treated animals became metabolic overachievers. They maintained higher core body temperatures in the cold, generated greater total energy expenditure, and resisted the weight gain and glucose intolerance induced by a high-fat diet. Human data added a correlative dimension: analysis of gene expression from public cohorts, including the Genotype-Tissue Expression project, showed that ALKBH5 levels in human subcutaneous fat inversely correlate with obesity, suggesting that the mouse findings may translate to human biology.

The deepest insight, however, came from the mechanistic work. Searching for the thermogenic machinery that ALKBH5 controls, the team landed on CKB, creatine kinase B, an enzyme central to the so-called futile creatine cycle. In this circuit, creatine kinase pumps phosphate onto creatine to build phosphocreatine, and a mitochondrial enzyme hydrolyzes it back again, forcing the cell to burn ATP in a loop that generates heat rather than useful work. Deleting ALKBH5 from fat lowered CKB expression and creatine kinase activity, while boosting ALKBH5 raised them. When the researchers depleted creatine with beta-guanidinopropionic acid, the thermogenic benefits of ALKBH5 overexpression largely evaporated, confirming that creatine metabolism is the load-bearing element of the pathway.

Molecularly, the connection between the demethylase and the creatine kinase is an elegant piece of RNA biology. ALKBH5 removes m6A marks from the CKB transcript itself. Those methyl tags, when present, are recognized by YTHDF2, a reader protein that escorts methylated mRNAs to degradation machinery. By demethylating CKB mRNA, ALKBH5 shields it from YTHDF2-mediated destruction, lengthening the transcript’s half-life and allowing more creatine kinase B protein to be produced. Experiments with mutated CKB constructs, methylated RNA immunoprecipitation, and YTHDF2 knockdown in both mouse brown and human beige adipocytes pieced this mechanism together site by site, and the m6A peaks identified on CKB mRNA matched the canonical DRACH sequence motifs predicted from genomic analysis.

Perhaps the most provocative result concerns UCP1, the long-reigning icon of thermogenesis. In mice genetically engineered to lack UCP1 entirely, ALKBH5 overexpression still raised energy expenditure and protected against cold exposure, demonstrating that the creatine-driven pathway operates in parallel with, and independently of, the classical uncoupling mechanism. This echoes recent single-cell studies suggesting that thermogenic fat contains distinct subpopulations of cells, some defined by UCP1 and others by futile cycling enzymes. The new work provides the first known regulatory link between an adrenergic signal and the creatine branch, effectively giving that parallel pathway its own commander.

The therapeutic implications are considerable. Obesity treatments based on increasing energy expenditure have long sought safe ways to activate thermogenic fat, but UCP1-centric strategies face hurdles, including uncertainty about how much functional brown fat adult humans carry and concerns about off-target adrenergic stimulation. A target that works through mRNA stabilization rather than receptor agonism, and that functions even without UCP1, opens a genuinely different door. The authors caution that ALKBH5 is a broad-acting demethylase implicated in diverse processes, from fertility to cancer metabolism to cardiac fibrosis, so any obesity therapy built on it would need careful tissue specificity. Still, the demonstration that a single RNA modification enzyme can rewire cellular fuel chemistry in response to cold reframes thermogenesis as an epitranscriptomic phenomenon, and it hands obesity researchers a new molecular lever precisely where they need it most: the fat that burns.

Subject of Research: The role of the m6A demethylase ALKBH5 in regulating creatine-driven non-shivering thermogenesis in adipose tissue

Article Title: ALKBH5 activates creatine-driven thermogenesis by stabilizing CKB mRNA in response to cold

Article References: Zhang, Y., Du, C., Qiao, W., Qiu, P., Xu, C., Yang, X., Hao, J., Zhao, D., Gai, X., & Chang, Y. (2026). ALKBH5 activates creatine-driven thermogenesis by stabilizing CKB mRNA in response to cold. Nature Metabolism. https://doi.org/10.1038/s42255-026-01592-y

Image Credits: AI Generated

DOI: 10.1038/s42255-026-01592-y

Keywords: ALKBH5, thermogenesis, brown fat, m6A methylation, CKB, creatine kinase, UCP1, obesity, YTHDF2, norepinephrine, CREB signaling, metabolism